Characterization of the bispecific VHH antibody tarperprumig (ALXN1820) specific for properdin and designed for low-volume administration

The bispecific antibody tarperprumig (ALXN1820) was developed as a treatment option for diseases involving dysregulated complement alternative pathway (AP) activity that could be administered in small volumes, either subcutaneously or intravenously. Tarperprumig incorporates a C-terminal variable do...

Descripción completa

Detalles Bibliográficos

Autores principales:	Paul Tamburini, Dennis Vestergaard Pedersen, Denise Devore, Josh Cone, Rekha Patel, Todd Hunter, Fang Sun, Gregers Rom Andersen, Jeffrey Hunter
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Taylor & Francis Group 2024-12-01
Colección:	mAbs
Materias:	Bispecific VHH antibody complement alternative pathway complement inhibition preclinical study properdin tarperprumig
Acceso en línea:	https://www.tandfonline.com/doi/10.1080/19420862.2024.2415060
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!